Chemomab Therapeutics (CMMB, Financial) has made significant changes to its leadership team to bolster its strategic direction. The company has appointed Dr. David Weiner as the Interim Chief Medical Officer (CMO). Dr. Weiner brings a wealth of experience to the role, aiming to guide the company's medical initiatives and research endeavors.
Additionally, Jack Lawler, who previously held the position of Senior Vice President of Global Medical Operations at Chemomab, has been promoted to Chief Development Officer (CDO). In his new role, Lawler will oversee the development strategies for Chemomab's pipeline projects, ensuring their progression aligns with the company's long-term goals.
These leadership changes come as Chemomab continues to focus on its mission to advance therapeutic solutions. The revamped executive team is expected to drive the company's efforts forward, enhancing the development and delivery of innovative treatments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Chemomab Therapeutics Ltd (CMMB, Financial) is $9.00 with a high estimate of $11.00 and a low estimate of $7.00. The average target implies an upside of 662.39% from the current price of $1.18. More detailed estimate data can be found on the Chemomab Therapeutics Ltd (CMMB) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Chemomab Therapeutics Ltd's (CMMB, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
